ATRX
Adhera Therapeutics, Inc.Company Information
- Company Name
- Adhera Therapeutics, Inc.
- CIK
- CIK0000737207
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ATRX: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ATRX
SEC filing data through
Insider Sentiment
- Last purchase
- 2017-06-09
- Last sale
- —
- Shares purchased (TTM)
- 1,012,118
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2023-12-31
- Institutional shares owned
- 1
- Shares outstanding
- 4,303,866
- Ownership
- 0.00%
Earnings Market Reaction
- Filing date
- 2023-11-20
- Price on filing date
- —
- 1-month reaction
- 62.50%
- 3-month reaction
- -8.75%
Balance Sheet
Values in millions ($)| Line item | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||||||
| Prepaid Expense And Other Assets Current | - | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Cash | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | ||||||
| Assets Current | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | |||||||||||||||||||
| Accounts Payable Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Due To Related Parties Current | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Current | - | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Accrued Liabilities Current | 6 | 5 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | ||||||
| Dividends Payable Current | 1 | 1 | 1 | 0 | 0 | 0 | 6 | 5 | 5 | 5 | 4 | 4 | 4 | ||||||
| Notes Payable | - | - | - | - | - | - | - | - | - | - | - | - | 6 | ||||||
| Notes Payable Current | - | - | - | - | - | - | - | - | - | - | 6 | 6 | - | ||||||
| Loans Payable Current | 10 | 9 | 8 | 7 | 7 | 6 | 6 | 6 | 6 | 6 | - | 6 | - | ||||||
| Convertible Notes Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 1 | - | ||||||
| Contract With Customer Liability Current | 0 | - | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Derivative Liabilities Current | 7 | 4 | 6 | 6 | 7 | 7 | 7 | 8 | 3 | 0 | - | - | - | ||||||
| Liabilities Current | 26 | 23 | 23 | 22 | 22 | 21 | 26 | 25 | 20 | 16 | 16 | 15 | 14 | ||||||
| Liabilities | 26 | 23 | 23 | 22 | 22 | 21 | 26 | 25 | 20 | 16 | 16 | 15 | 14 | ||||||
Stockholders Equity | |||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 34 | 34 | 34 | 34 | 34 | 33 | 28 | 28 | 31 | 30 | 30 | 30 | 30 | ||||||
| Treasury Stock Value | -0 | -0 | -0 | -0 | -0 | -0 | - | - | - | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -60 | -56 | -57 | -56 | -55 | -54 | -53 | -53 | -51 | -47 | -46 | -45 | -44 | ||||||
| Stockholders Equity | -26 | -23 | -23 | -22 | -22 | -20 | -25 | -25 | -20 | -16 | -16 | -15 | -14 | ||||||
| Liabilities And Stockholders Equity | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 180 | ||||||
| Common Stock Shares Issued | 5 | 4 | 3 | 3 | 3 | 3 | 1 | 1 | 1 | - | 1 | 1 | 1 | ||||||
| Shares Outstanding | 5 | 4 | 3 | 3 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Treasury Stock Shares | - | - | - | 0 | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAdhera Therapeutics, Inc. (ATRX) — SEC Financial Statements & Analysis
Adhera Therapeutics, Inc. (ATRX) is a pharmaceutical preparations company, incorporated in DE. Adhera Therapeutics, Inc. trades on OTC as: ATRX. Adhera Therapeutics, Inc. (ATRX)'s most recent SEC filing is a Form 10-Q for the period ended 2023-09-30, filed with the SEC on 2023-11-20. Based on that filing, Adhera Therapeutics, Inc. carries a market cap of $129.12K, a P/E ratio of -0.03x, a P/B ratio of -0.00x, a P/S ratio of 3.83x, an enterprise value of $10.93M, and an EV/EBITDA multiple of -8.54x. On profitability, it posts an operating margin of -4263.64%, a net margin of -6153.03%, a Return on Equity (ROE) of 15.52%, and a Return on Assets (ROA) of -2488.56%. Per share, it reports EPS of $-0.87, diluted EPS of $-0.87, free cash flow per share of $-0.17, and a dividend per share of $0.03. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -40.56% year-over-year, and EPS growth of -56.34% year-over-year. On the balance sheet, it maintains a current ratio of 0.00x, a quick ratio of 0.00x, working capital of $-26.32M, a debt-to-equity ratio of -1.00x, a debt ratio of 598.07, free cash flow of $-714.19K (TTM), and net debt of $10.80M. Figures sourced from SEC EDGAR.
- Market Cap
- $129.12K
- P/E TTM
- -0.03x
- EPS TTM
- $-0.87
- P/B TTM
- -0.00x
- ROE TTM
- 15.52%
- ROA TTM
- -2488.56%
- Debt To Equity
- -1.00x
- Free Cash Flow TTM
- $-714.19K
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2023-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Adhera Therapeutics, Inc. in?
Adhera Therapeutics, Inc. (ATRX) operates in the Pharmaceutical Preparations industry.
What exchange does ATRX trade on?
Adhera Therapeutics, Inc. (ATRX) trades on the OTC.
Where is Adhera Therapeutics, Inc. incorporated?
Adhera Therapeutics, Inc. is incorporated in DE.
When was Adhera Therapeutics, Inc. (ATRX)'s most recent SEC filing?
Adhera Therapeutics, Inc. (ATRX)'s most recent SEC filing is a Form 10-Q for the period ended 2023-09-30, filed with the SEC on 2023-11-20.
What is ATRX's market cap?
Adhera Therapeutics, Inc. (ATRX) has a market capitalization of $129.12K as of 2023-09-30.
What is ATRX's EPS (earnings per share)?
Adhera Therapeutics, Inc. (ATRX)'s trailing twelve month EPS is $-0.87 as of 2023-09-30.
What is ATRX's ROE (return on equity)?
Adhera Therapeutics, Inc. (ATRX)'s trailing twelve month Return on Equity (ROE) is 15.52% as of 2023-09-30.
What is ATRX's ROA (return on assets)?
Adhera Therapeutics, Inc. (ATRX)'s trailing twelve month Return on Assets (ROA) is -2488.56% as of 2023-09-30.
What is ATRX's EV/EBITDA?
Adhera Therapeutics, Inc. (ATRX)'s trailing twelve month EV/EBITDA is -8.54x as of 2023-09-30.